Premenstrual and postpartum mood disorders

Current Opinion in Psychiatry

Volumn 9, Issue 1, 1996, Pages 11-16

  Parry, Barbara L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; DANAZOL; FLUOXETINE; GOSERELIN; MIFEPRISTONE; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR;

AMENORRHEA; DEPRESSION; DISEASE CLASSIFICATION; FEMALE; HUMAN; MOOD; PATHOGENESIS; PREMENSTRUAL SYNDROME; PUERPERAL DEPRESSION; PUERPERAL PSYCHOSIS; REVIEW; SIDE EFFECT;

EID: 0030025355     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-199601000-00003     Document Type: Review

References (33)

1. ICD-10: International Classification of Diseases. Geneva: World Health Organization; 1994.
2. Diagnostic and Statistical Manual of Mental Health Disorders, edn 3, revised. Washington, DC: American Psychiatric Association; 1993.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Press; 1944.
4. Bancroft F, Rennie D, Warner P: Vulnerability to perimenstrual mood change: the relevance of a past history of depressive disorder. Psychosom Med 1994, 56:225-231.
5. Schmidt PJ, Purdy RH, Moore PH, Paul SM, Rubinow DR: Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994, 79:1256-1260.
6. Facchinetti F, Fioroni L, Martignoni E, Sances G, Costa A, Genazzani A: Changes of opioid modulation of the hypothalamo-pituitary-adrenal axis in patients with severe premenstrual syndrome. Psychosom Med 1994, 56:418-422.
7. Menkes DB, Coates DC, Fawcett JP: Acute tryptophan depletion aggravates premenstrual syndrome. J Affective Disord 1994, 32:37-44.
8. Eriksson E, Alling C, Andersch B, Andersson K, Berggren U: Cerebrospinal fluid levels of monoamine metabolites. Neuropsychopharmacol 1994, 11:201-213.
9. Altshuler LA, Hendrick V, Parry B: Pharmacological management of premenstrual disorder. Harvard Rev Psychiatry 1995, 2:233-245. The authors thoroughly and extensively review the pharmocological management of premenstrual dysphoric disorder and include summary tables, treatment guidelines, and critiques.
10. Severino SK, Moline ML: Premenstrual syndrome: Identification and management. Pract Therapeut Drugs 1995, 49:71-82.
11. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, Grover G, Streiner D: Fluoxetine in the treatment of premenstrual dysphoria. N Engl J Med 1995, 332:1529-1534. This study is a large-scale Canadian trial, in which the authors report the superior efficacy of fluoxetine compared with placebo in the treatment of premenstrual dysphoria, and the equal efficacy with fewer side effects of 20 mg compared with 60 mg.
12. Rubinow DR, Schmidt PJ: The treatment of premenstrual syndrome - forward into the past. N Engl J Med 1995, 332:1574-1575. This excellent editorial puts the biological and treatment studies of premenstrual syndrome in perspective with putative changes during the menstrual cycle.
13. Pearlstein T, Stone AB: Long-term fluoxetine treatment of late luteal phase dysphoric disorder. J Clin Psychiatry 1994, 55: 332-335.
14. Stewart DE, Fairman M, Barbadoro S, Zownir P, Steiner M: Follicular and late luteal phase serum fluoxetine levels in women suffering from late luteal phase dysphoric disorder. Biol Psychiatry 1994, 36:201-202.
15. West CP, Millier H: Ovarian suppression with the gonadotrophin-releasing hormone agonist goserelin (Zoladex) in management of the premenstrual tension syndrome. Hum Reproduc 1994, 9:1058-1063.
16. Chan AF, Mortoala JF, Wood SH, Yen SSC: Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 1994, 84:1001-1006.
17. Hahn P, Van Vugt DA, Reid RL: A randomized, placebo-controlled, cross-over trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinol 1995, 20:193-209.
18. Berger CP, Presser B: Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. Obstet Gynecol 1994, 84: 379-385.
19. Freeman EW, Rickels K, Sondheimer SJ, Denis A. Pfeifer S, Weil S: Nefazadone in the treatment of premenstrual syndrome: a preliminary study. J Clin Psychopharmacol 1994, 14:180-186.
20. Steinberg S, Annable L, Young SN, Belanger MC: Tryptophan in the treatment of late luteal phase dysphoric disorder: a pilot study. J Psychiatr Neurosci 1994, 19:114-119.
21. Cooper PJ, Murray L: Course and recurrence of postnatal depression: evidence for the specificity of the diagnostic concept. Br J Psychiatry 1995, 166:191-195. The authors showed that women with postpartum depression are more likely to have a recurrence of depression in future postpartum periods, whereas women with previous histories of affective illness are more likely to have recurrences of depression outside of the postpartum period.
22. Brockington IF, Meakin CJ: Clinical clues to the aetiology of puerperal psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:417-429.
23. Wisner KL, Wheeler SB: Prevention of recurrent postpartum major depression. Hosp Community Psychiatry 1994, 45:1191-1196. An important clinical treatment study suggesting the efficacy of prophylactic antidepressant medication in the prevention of recurrent postpartum major depression.
24. Schopf J, Rust B: Follow-up and family study of postpartum psychoses. Part II: Early versus late onset postpartum psychoses. Eur Arch Psychiatry Clin Neurosci 1994, 244:135-137.
25. Schopf J, Rust B: Follow-up and family study of postpartum psychoses. Part III: Characteristics of psychoses occurring exclusively in relation to childbirth. Eur Arch Psychiatry Clin Neurosci 1994, 244:138-140.
26. Schopf J, Rust B: Follow-up and family study of postpartum psychoses. Part IV: Schizophreniform psychoses and brief reactive psychoses: lack of nosological relation to schizophrenia. Eur Arch Psychiatry Clin Neurosci 1994, 244:141-144.
27. Coble PA, Reynolds CF, Kupfer DJ, Houck PR, Day NL, Giles DE: Childbearing in women with and without a history of affective disorder. II. Electroencephalographic sleep. Compr Psychiatry 1994, 35:215-224. The authors showed that women with a history of affective illness have more sleep disturbances, particularly shortened rapid eye-movement latency, during late gestation and for up to 8 months postpartum compared with women without such histories. These findings support rapid eye-movement latency as a vulnerability marker for depressive illness.
28. Appleby L, Gregoire A, Platz C, Prince M, Kumar R: Screening women for high risk of postnatal depression. J Psychosomatic Res 1994, 38:539-545.
29. Glover V, Liddle P, Taylor A, Adams D, Sandler M: Mild hypomania (the highs) can be a feature of the first postpartum week. Association with later depression. Br J Psychiatry 1994, 164:517-521.
30. Kumar R: Postnatal mental illness: a transcultural perspective. Soc Psychiatry Psychiatr Epidemiol 1994, 29:250-264. The authors examine the possible cultural influences on postnatal depression and psychosis and, contrary to expectation, report consistent rates.
31. Wisner KL, Peindl K, Harasa BH: Symptomatology of affective and psychiatric illnesses related to childbearing. J Affective Disord 1994, 30:77-87. A careful study examining the specific symptomatology of postpartum depression and psychoses, supporting the development of diagnostic criteria.
32. Ballard CG, Daves R, Cullen PC, Mohan RN, Dean C: Prevalence of postnatal psychiatric morbidity in mothers and fathers. Br J Psychiatry 1994, 164:782-788.
33. Parry BL, Rousch J: Premenstrual dysphoria disorder. In Comprehensive textbook of psychiatry Edition 6. Edited by Kaplam HI, Sadock BJ. Baltimore: Williams and Wilkins; 1994.